Eagle Pharmaceuticals (EGRX) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2017 Results
February 26, 2018 6:50 AM EST-- Record 2017 revenue of $237 million
--Q4 2017 net income of $0.58 per diluted share and Adjusted Non-GAAP net income of $1.00 per diluted share --
-- FY 2017 net income of $3.27 per diluted share and Adjusted Non-GAAP net income of $4.34 per diluted share --
-- Agreed on path forward with the FDA for an additional clinical trial for RYANODEX for Exertional Heat Stroke --
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals, Inc. (Eagle or the Company) (Nasdaq: EGRX) today announced its financial results for the... More
